Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sumatriptan
Drug ID BADD_D02098
Description Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.[A179761] Sumatriptan was granted FDA approval on 28 December 1992.[L6805]
Indications and Usage A combination sumatriptan and [naproxen] tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older.[L6793] Sumatriptan nasal powder, nasal spray, subcutaneous injection, and tablets are indicated to treat migraines with or without auras in adults.[L6796,L6799,L6805,L6808,L6811] One of the subcutaneous formulations of sumatriptan is also indicated to treat cluster headaches in adults[L6805], while the other subcutaneous formulation is not.[L6808]
Marketing Status approved; investigational
ATC Code N02CC01
DrugBank ID DB00669
KEGG ID D00451
MeSH ID D018170
PubChem ID 5358
TTD Drug ID D0Z6UC
NDC Product Code 80425-0258; 52932-0733; 42043-220; 65145-118; 72189-404; 62331-048; 42043-222; 55150-173; 55700-969; 63629-8701; 0173-0737; 55700-918; 70069-804; 0527-1859; 63304-097; 69452-344; 0480-2014; 45802-619; 0173-0736; 0245-0812; 60429-995; 63304-098; 63304-099; 53873-058; 67835-5011; 0173-0479; 0173-0524; 66993-084; 0527-1818; 36000-289; 66993-082; 69452-345; 69452-346; 71921-170; 58437-017; 0143-9638; 0173-0523; 63187-164; 63187-323; 63629-8703; 69097-644; 80425-0318; 50370-0029; 53873-057; 58437-016; 58437-018; 0173-0735; 53002-3562; 66993-083; 80425-0224; 53873-059; 42043-221; 0173-0478; 66993-081; 68071-2825; 0480-2013; 45802-598; 0173-0739
UNII 8R78F6L9VO
Synonyms Sumatriptan | 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide | Sumatriptan Succinate | Succinate, Sumatriptan | GR-43175 | GR 43175 | GR43175 | Imigran
Chemical Information
Molecular Formula C14H21N3O2S
CAS Registry Number 103628-46-2
SMILES CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscle fatigue15.05.03.006--Not Available
Upper respiratory tract inflammation22.12.03.034--Not Available
Muscle tightness15.05.03.007--Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Application site paraesthesia17.02.06.012; 12.07.01.026; 08.02.01.026--Not Available
Electrocardiogram T wave abnormal13.14.05.009--
Contusion24.07.06.001; 23.03.11.002; 12.01.06.001; 15.03.05.007--
Skin tightness23.03.03.018--Not Available
Fluid imbalance14.05.01.003--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000056%Not Available
Fallopian tube disorder21.11.02.002--Not Available
Ear congestion04.03.01.010--Not Available
Eye oedema06.08.03.013--Not Available
Eye pruritus06.04.05.006--Not Available
Nasal discomfort22.12.03.0120.000189%Not Available
Drug tolerance increased08.06.01.004--Not Available
Oral pruritus07.05.05.002--Not Available
Musculoskeletal stiffness15.03.05.0270.000178%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Walking disability26.01.01.009--Not Available
Extraocular muscle disorder15.05.05.004; 06.05.02.005--Not Available
Nodule08.03.05.002--Not Available
Phonophobia19.06.03.003; 04.03.01.008--Not Available
Haemorrhage24.07.01.002--Not Available
Temperature intolerance08.01.09.022--Not Available
Hypoaesthesia oral07.05.05.003; 17.02.06.021--Not Available
Vasodilation procedure25.03.01.001--Not Available
Application site discolouration12.07.01.030; 08.02.01.030; 23.03.03.023--Not Available
Cerebral vasoconstriction24.04.06.025; 17.08.02.0120.000139%Not Available
Cluster headache17.14.01.003--Not Available
The 13th Page    First    Pre   13 14 15    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene